Sort
39,280 grants matching “leukemia”
Novel pro-survival mechanisms of PIM2 in multiple myeloma
$596,594Kelvin P Lee · Indiana University Indianapolis · R01 · FY2023 · CA
Outcomes for CLL patients treated with novel therapy
$596,539Neil E Kay · Mayo Clinic Rochester · R01 · FY2024 · CA
Project 2: : Systematic discovery of cell-extrinsic mechanisms of cancer drug resistance
$596,423Alex K Shalek · Massachusetts Institute Of Technology · U54 · FY2019 · CA
Molecular library screening by MALDI-TOF scanning of fu*
$596,274Stephen J. Kron · University Of Chicago · R01 · FY2006 · HG
Squamous Cell Carcinoma of the Lung: Validation of Molecular Signatures for Progn
$596,174Fred R Hirsch · University Of Colorado Denver · U01 · FY2016 · CA
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms
$596,157Jaroslaw P Maciejewski · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · CA
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms
$596,157Jaroslaw P Maciejewski · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · CA
Unlocking the Potential of PI3K Inhibition in CLL
$596,117Jennifer R Brown · Dana-Farber Cancer Inst · R01 · FY2018 · CA
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
$595,903Katharine C Hsu · Sloan-Kettering Inst Can Research · R01 · FY2023 · HL
TRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPY
$595,787Todd A Fehniger · Washington University · R01 · FY2019 · CA
VLA-4âtargeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
$595,764Ravi Bhasker Patel · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Structural insights into the MLL core complexes
$595,749Yali Dou · University Of Southern California · R01 · FY2023 · CA
AML mutation-guided drugging of DNA repair
$595,466Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2020 · CA
"Off-the-Shelf" iPSC-Derived Regulatory T Cell Immunotherapeutics
$595,443Bruce R. Blazar · University Of Minnesota · P01 · FY2023 · CA
Unlocking the Potential of PI3K Inhibition in CLL
$595,146Jennifer R Brown · Dana-Farber Cancer Inst · R01 · FY2017 · CA
Exploring and Exploiting APOBEC3G Biology
$595,061Warner C Greene · J. David Gladstone Institutes · R56 · FY2009 · AI
Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization
$595,044Suming Huang · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2024 · CA
Pathogenic consequences of altered insulin signaling in the diabetic brain.
$595,009Paul M. Mathews · Nathan S. Kline Institute For Psych Res · R56 · FY2018 · AG
Pre-malignant mutation landscape and risk factors for progression to hematologic cancers
$594,978Pinkal Desai · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Improving risk allocation and developing novel therapies for children with T-ALL
$594,741David T. Teachey · Children'S Hosp Of Philadelphia · R01 · FY2018 · CA
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
$594,545Michael J Thirman · University Of Chicago · R01 · FY2021 · CA
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
$594,545Michael J Thirman · University Of Chicago · R01 · FY2018 · CA
Instructive role of MLL fusion proteins in lineage determination and leukemogenesis
$594,545Michael J Thirman · University Of Chicago · R01 · FY2020 · CA
Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric
$594,462Heike Elizabeth Daldrup-Link · Stanford University · R01 · FY2024 · CA
Reprogram long-lived effector T cells for cancer immunotherapy
$594,393Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2021 · CA